STOCK TITAN
  1. Home
  2. News
  3. CMMB

Chemomab to Present at Stifel 2021 Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

TEL AVIV, Israel, Nov. 9, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced it will host a live presentation and participate in 1-on-1 investor meetings at Stifel's 2021 Virtual Healthcare Conference.

Chemomab Logo

Presentation details:

Date:                  November 15, 2021
Time:                 8:00 AM ET
Presenters:       Dr. Dale Pfost, CEO, and Dr. Adi Mor, CSO
Webcast Link:  Click here

The presentation will be available for 60 days following the conference at the Events section of the Chemomab website.

About Chemomab Therapeutics Ltd.

Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in two Phase 2 safety and efficacy trials--one in patients with primary sclerosing cholangitis (PSC) and the second in patients with liver fibrosis, with a third Phase 2 trial in systemic sclerosis expected to begin early in 2022.

For more information on Chemomab, visit chemomab.com.

Contacts:

Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1-917-734-7387
ir@chemomab.com

Media:
Barbara Lindheim
BLL Partners for Chemomab
Phone: +1-917-355-9234 
blindheim@bllbiopartners.com

Cision View original content:https://www.prnewswire.com/news-releases/chemomab-to-present-at-stifel-2021-virtual-healthcare-conference-301419442.html

SOURCE ChemomAb Ltd.

Stock CMMB logo
Chemomab Therapeutics Ltd. American Depositary Share

NASDAQ:CMMB

CMMB Rankings

#5363 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

CMMB Latest News

May 9, 2024
Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 8, 2024
Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
May 2, 2024
Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
Apr 24, 2024
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
Apr 18, 2024
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

CMMB Stock Data

11.52M
187.84M
14.99%
24.96%
1.63%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
TEL AVIV

About CMMB

chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis).